Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

been added to

diluted weighted average shares outstanding for both of these periods

for purposes of computing diluted earnings per share.

GENZYME CORPORATION (GENZ)

Condensed Consolidated Balance Sheets March 31, December 31,

(Unaudited, amounts in thousands) 2008 2007

Cash and all marketable securities $1,447,983 $1,460,394

Other current assets 1,818,541 1,661,740

Property, plant and equipment, net 2,118,960 1,968,402

Intangibles, net (1) 3,386,451 2,959,480

Other assets (2) 311,581 251,725

Total assets $9,083,516 $8,301,741

Current liabilities $1,475,663 $1,502,406

Noncurrent liabilities (1) 658,936 186,398

Stockholders' equity 6,948,917 6,612,937

Total liabilities and stockholders'

equity $9,083,516 $8,301,741

(1) Effective January 1, 2008, in connection with the restructuring of

BioMarin/Genzyme LLC, our joint venture with BioMarin Pharmaceutical

Inc., we licensed certain rights to commercialize Aldurazyme from the

joint venture and, in accordance with the provisions of FASB

Interpretation No. 46R, "Consolidation of Variable Interest Entities,"

began consolidating the results of the joint venture at fair value. As

of March 31, 2008, intangibles, net, includes $480,500K for the fair

value of the joint venture's manufacturing and commercialization

rights to Aldurazyme, offset by $(6,006)K of related accumulated

amortization. Noncurrent liabilities includes $474,494K of additional

net liabilities relat
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Vital Imaging ™ has teamed ... San Diego for a joint study which aims to ... Resonance Imaging) with that of a supine Dynawell MRI ... of improved healthcare by combining cutting edge technology with ... valuable tool for evaluating pathological changes in the spine, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Clinovo's ... an 8-week training program starting on June 11th, 2013. ... clinical trial professionals reach the next step in their ... Offices in Palo Alto, and streamed online. , Taught ... award-winning papers, Clinovo's new “CDISC Standards: Theory and Application” ...
(Date:5/20/2013)... May 20, 2013 Today, at the American ... , James McGough , M.D., ... the Semel Institute for Neuroscience and Human Behavior and ... at the University of California Los Angeles (UCLA), and ... Adolescent Psychopharmacology and ADHD at UCLA, presented the results ...
(Date:5/20/2013)... ROCKVILLE , Md. and BALTIMORE ... Inc. (BHI), a regional private-public partnership focusing ... to early-stage funding in Central Maryland ... Aiyar, Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) ... (NIH) National Heart, Lung and Blood Institute ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3Clinovo Launches TechTrainings on CDISC Standards 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4
...  HistoRx recently licensed from Yale University a new clinical ... doctors treating patients with melanoma to identify a subset ... in their lymph nodes, have a 40% risk of ... quantitative IHC testing method that enables measurement of protein ...
... 2011 Ambry Genetics, a global leader in ... they have officially launched their Illumina MiSeq Next-Gen ... adapter of Illumina sequencing systems since 2007 and ... processing thousands of samples. (Logo:  ...
... BOSTON, Dec. 21 , 2011  To help ... challenging regulatory and commercial environment, PAREXEL International ... global biopharmaceutical services provider, today announced that it ... clinical operations and outsourcing leaders worldwide.  During these ...
Cached Biology Technology:HistoRx Licenses Melanoma Assay from Yale University 2Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services 2PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes 2PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes 3PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes 4
(Date:5/20/2013)... articles posted online ahead of print 9 ... of geoscience subdisciplines, including minerals exploration, archaeology, planetary ... include Siberia; the Sumatran subduction margin; the Monte ... and the Southeastern U.S. Atlantic Margin. Brief highlights ... tectonics;, 2. The clear fingerprint of ice ages ...
(Date:5/19/2013)... electricity-producing bacteria that can grow using hydrogen gas as ... sole source of carbon. Researchers at the University ... General Meeting of the American Society for Microbiology. , ... on hydrogen," says Amit Kumar, a researcher on the ... the Lovley Lab Group at the university. , Under ...
(Date:5/18/2013)... 19, 2013) The AGA Research Foundation is honored ... Augustyn Award in Digestive Cancer, which will support Andrew ... at the University of Pennsylvania, Philadelphia, as he furthers ... development, regeneration and cancer progression. , "The AGA Research ... of two distinguished clinicians and AGA Legacy Society members," ...
Breaking Biology News(10 mins):New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11AGA Research Foundation grant furthers digestive cancer research 2
... 2011 Employing technology that reads the entire DNA ... (TGen) and the Technical University of Denmark (DTU) have ... that killed more than 6,000 people and sickened 300,000. ... billions of chemical bases in DNA, TGen and DTU ...
... Salmonella have a sneaky way of making minor alterations to ... a fascinating discovery made at Ohio State University, which is ... Biology. This discovery shows how bacteria make tweaks in ... team includes research scientist Herve Roy, who joined the University ...
... BOSTON -- Aug. 22, 2011 -- Researchers at the Joslin ... mitochondria of cells is decreased in the skeletal muscle of ... development of drugs to boost the activity of this enzyme ... in published online today in the Proceedings of the National ...
Cached Biology News:TGen and DTU researchers track source of Haitian cholera outbreak 2TGen and DTU researchers track source of Haitian cholera outbreak 3Newfound hijacked proteins linked to salmonella virulence 2Joslin researchers identify new target for treatment of type 2 diabetes and prediabetes 2
... The Flat Block Moto Alpha unit with motorized ... flat surface that is useful for microarrays and ... customized sample blocks. The sealing force of the ... actively measured to give repeatable results. This interchangeable ...
... Anti-Krueppel-like factor 15 (KLF15) KLF15 ... is found abundantly expressed in the liver, ... #: NP_054798 Specificity: Polyclonal antibody produced ... corresponding to a region of human KLF15 ...
... Affi-Prep protein A media yield highly ... prior to analysis of other immunoglobulin ... antigen purification. Protein A binds to ... IgG from mammalian species. This ready-to-use, ...
... is a new tuning and calibration standard ... spectrometry. Accumix is a lyophilized 7-peptide ... for both tuning and calibration of ion ... Fourier transform mass spectrometers. Direct infusion ...
Biology Products: